Top

Journal of Diabetes & Metabolic Disorders

Published in:

Open Access 01-12-2015 | Review

Targeting metabolic disorders by natural products

Authors: Ozra Tabatabaei-Malazy, Bagher Larijani, Mohammad Abdollahi

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2015

Abstract

The most prevalent metabolic disorders are diabetes mellitus, obesity, dyslipidemia, osteoporosis and metabolic syndrome, which are developed when normal metabolic processes are disturbed. The most common pathophysiologies of the above disorders are oxidative stress, Nrf2 pathways, epigenetic, and change in miRNA expression. There is a challenge in the prevention and treatment of metabolic disorders due to severe adverse effects of some synthetic drugs, their high cost, lack of safety and poverty in some conditions, and insufficient accessibility for the general population in the world. With increasing interest in shifting from synthetic drugs to phytotherapy as an alternative treatment, there is still a gap in scientific evidences of plant-derived therapeutic benefits. One reason may be slow rate of translation of animal studies’ findings into human clinical trials. Since metabolic disorders are multifactorial, it seems that poly-herbal medications, or drug-herbal combination are needed for their treatment. However, further researches to determine the most effective plant-derived metabolites, and their cellular mechanism in order to set priorities for well-designed animal and clinical trials, and also more studies with strong scientific evidences such as systematic review and meta-analysis of controlled studies are needed.

Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75:311–35.PubMedPubMedCentralCrossRef

Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery. Eur J Med Chem. 2011;46:4769–807. doi:https://doi.org/10.1016/j.ejmech.2011.07.057.PubMedCrossRef

Harvey AL. Natural products in drug discovery. Drug Discov Today. 2008;13:894–901. doi:https://doi.org/10.1016/j.drudis. 2008.07.004.PubMedCrossRef

WHO. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation, Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.

DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med. 2010;123:S38–48. doi:https://doi.org/10.1016/j.amjmed.2009.12.008.PubMedCrossRef

Executive summary IDF Diabetes Atlas 6^th Edition: International Diabetes Federation. www.idf.org/sites/default/files/EN_6E_Atlas_Exec_Sum_1.pdf. accessed 2014.

Rahimi R, Nikfar SH, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365–73.PubMedCrossRef

Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol. 2006;212:167–78.PubMedCrossRef

Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J. The role of oxidative stress and antioxidants in diabetic complications. Sultan Qaboos Univ Med J. 2012;12:5–18.PubMedPubMedCentralCrossRef

10.

Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 2005;4:5. doi:https://doi.org/10.1186/1475-2840-4-5.PubMedPubMedCentralCrossRef

11.

Kaneto H, Katakami N, Matsuhisa M, Matsuoka TA: Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm 2010;2010:453892. doi:https://doi.org/10.1155/2010/453892.

12.

Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun. 2013;433:359–61. doi:https://doi.org/10.1016/j.bbrc.2013.02.120.PubMedCrossRef

13.

Lupi R, DelPrato S. β-cell apoptosis intype 2 diabetes: quantitative and functional consequences. Diabetes Metab. 2008;34:S56–64. doi:https://doi.org/10.1016/S1262-3636(08)73396-2.PubMedCrossRef

14.

Mohseni-Salehi-Monfared SS, Larijani B, Abdollahi M. Islet transplantation and antioxidant management: a comprehensive review. World J Gastroentrol. 2009;15:1153–61.CrossRef

15.

Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, et al. β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol. 2011;178:2632–40. doi:https://doi.org/10.1016/j.ajpath.2011.02.036.PubMedPubMedCentralCrossRef

16.

Mates JM, Segura JA, Alonso FJ, Marquez J. Oxidative stress in apoptosis and cancer: an update. Arch Toxicol. 2012;86:1649–65.PubMedCrossRef

17.

Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes. 2009;58:2718–25.PubMedPubMedCentralCrossRef

18.

Calvanese V, Lara E, Kahn A, Fraga MF. The role of epigenetics in aging and age-related diseases. Aging Res Rev. 2009;8:268–76.CrossRef

19.

Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol. 2010;299:F14–25.PubMedPubMedCentralCrossRef

20.

Jiang YH, Bressler J, Beauder AL. Epigenetics and human diseases. Annu Rev Genomics Hum Genet. 2004;5:479–510.PubMedCrossRef

21.

Johnstone SE, Baylin SB. Stress and the epigenetic landscape:a link to the pathobiology of human diseases? Nat Rev Genet. 2010;11:806–12.PubMedPubMedCentralCrossRef

22.

Blade C, Baselga-Escudero L, Salvadó MJ, Arola-Arnal A. MiRNA, polyphenols, and chronic disease. Mol Nutr Food Res. 2013;57:58–70. doi:https://doi.org/10.1002/mnfr.201200454.PubMedCrossRef

23.

Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus: a microRNA-related disease? Transl Res. 2011;157:253–64.PubMedCrossRef

24.

Rotters V, Naar AM. MicroRNA in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13:239–50.CrossRef

25.

Bhakkiyalakshmi E, Sireesh D, Rajaguru P, Paulmurugan R, Ramkumar KM. The emerging role of redox-sensitive Nrf2–Keap1 pathway in diabetes. Pharmacol Res. 2014;S1043-6618(14):00165. doi:https://doi.org/10.1016/j.phrs.2014.10.004.

26.

Sedeek M, Montezano AC, Hebert RL, Gray SP, Di Marco E, Jha JC, et al. Oxidative stress, Nox isoforms and complications of diabetes-potential targets for novel therapies. J Cardiovasc Transl Res. 2012;5:509–18. doi:https://doi.org/10.1007/s12265-012-9387-2.PubMedCrossRef

27.

He ZX, Zhou ZW, Yang Y, Yang T, Pan SY, Qiu JX, et al. Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42:125–38. doi:https://doi.org/10.1111/1440-1681.12332.PubMedCrossRef

28.

Nissa M. Review of current and emerging therapies in type 2 diabetes mellitus. Am J Manag Care. 2012;18:S17–26.

29.

Raalte DHV, Diamant M. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? Diabet Res Clin Pract. 2011;93:S37–46.CrossRef

30.

Rochette L, Zeller M, Cottin Y, Vergely C. Diabetes, oxidative stress and therapeutic strategies. Biochim Biophys Acta. 1840;2014:2709–29. doi:https://doi.org/10.1016/j.bbagen.2014.05.017.

31.

De Jager J, Kooy A, Schalkwijk C, van der Kolk J, Lehert P, Bets D, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014;275:59–70. doi:https://doi.org/10.1111/joim.12128.PubMedCrossRef

32.

Elmali E, Altan N, Bukan N. Effect of the sulphonylurea glibenclamide on liver and kidney antioxidant enzymes in streptozotocin-induced diabetic rats. Drugs R D. 2004;5:203–8.PubMedCrossRef

33.

Tuzun C, Girgin FK, Sozmen EY, Mentes G, Ersoz B. Antioxidant status inexperimental type 2 diabetes mellitus: effect of glibenclamide and glipizide on various rat tissues. Exp Toxicol Pathol. 1999;51:436–41.PubMedCrossRef

34.

Barac A, Campia U, Matuskey LA, Lu L, Panza JA. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Am J Cardiol. 2008;101:980–5. doi:https://doi.org/10.1016/j.amjcard.2007.11.058.PubMedCrossRef

35.

Gupta M, Teoh H, Kajil M, Tsigoulis M, Quan A, Braga MF, et al. The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients. Exp Clin Cardiol. 2012;17:191–6.PubMedPubMedCentral

36.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.PubMedCrossRef

37.

Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone:a meta-analysis. JAMA. 2007;298:1189–95.PubMedCrossRef

38.

Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preserving β-cell function in type 2 diabetes mellitus. Drugs. 2005;65:1–13.PubMedCrossRef

39.

Gumieniczek A, Owczarek B, Pawlikowska B: Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide. Exp Diabetes Res 2012;2012:653678. doi:https://doi.org/10.1155/2012/653678.

40.

Bethel MA, Xu W, Theodorakis MJ. Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus. Diabetes Obes Metab. 2014. doi:https://doi.org/10.1111/dom.12401.

41.

Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–37. doi:https://doi.org/10.1016/j.cmet.2013.04.008.PubMedCrossRef

42.

Triplitt CL. New technologies and therapies in the management of diabetes. Am J Manag Care. 2007;13:S47–54.PubMed

43.

Nikfar S, Abdollahi M, Salari P. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. J Pharm Pharm Sci. 2012;15:1–30.PubMedCrossRef

44.

Salari P, Nikfar S, Abdollahi M. No superiority of exenatide over insulin in diabetic patients in terms of weight reduction or incidence of adverse effects: A meta-analysis. Int J Pharmacol. 2011;7:749–56. doi:https://doi.org/10.3923/ijp.2011.749.756.CrossRef

45.

Lorenzi GM, LaRue SM, Collins SE. Effects of a patient education support program on pramlintide adherence. Clinical Diabetes. 2011;29:17–24. doi:https://doi.org/10.2337/diaclin.29.1.17.CrossRef

46.

Kikuchi K, Tancharoen S, Takeshige N, Yoshitomi M, Morioka M, Murai Y, et al. The efficacy of Edaravone (Radicut), a free radical scavenger, for cardiovascular disease. Int J Mol Sci. 2013;14:13909–30. doi:https://doi.org/10.3390/ijms140713909.PubMedPubMedCentralCrossRef

47.

Akash MS, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonists: a new therapy for type 2 diabetes mellitus. J Pharm Sci. 2012;101:1647–58. doi:https://doi.org/10.1002/jps.23057.PubMedCrossRef

48.

Xu R, Zhang S, Tao A, Chen G, Zhang M. Influence of vitamin E supplementation on glycemic control: a meta-analysis of randomized controlled trials. PLoS ONE. 2014;9, e95008. doi:https://doi.org/10.1371/journal.pone.0095008.PubMedPubMedCentralCrossRef

49.

Tabatabaei-Malazy O, Nikfar S, Larijani B, Abdollahi M. Influence of ascorbic acid supplementation on type 2 diabetes mellitus in observational and randomized controlled trials; a systematic review with meta-analysis. J Pharm Pharm Sci. 2014;17:554–82.PubMedCrossRef

50.

Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation. 2012;122:S66–73.

51.

Larijani B, Afshari M, Astanehi-Asghari F, Mojtahedi A, Rezaie A, Hosseinnezhad A, et al. Effect of short-term carvedilol therapy on salivary and plasma oxidative stress parameters and plasma glucose level in type II diabetes. Therapy. 2006;3:119–23.CrossRef

52.

DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O’Keefe JH. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am J Cardiol. 2013;111:765–9.PubMedCrossRef

53.

Nyenwe BA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011;60:1–23. doi:https://doi.org/10.1016/j.metabol.2010.09.010.PubMedPubMedCentralCrossRef

54.

Dietrich E, Powell J, Taylor JR. Canagliflozin: a novel treatment option for type 2 diabaetes. Drug Des Devel Ther. 2013;7:1399–408. doi:https://doi.org/10.2147/DDDT.S48937.PubMedPubMedCentralCrossRef

55.

Abdollahi M, Chan TS, Subrahmanyam V, Obrien PJ. Effects of phosphodiesterase 3, 4, 5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem. 2003;252:205–11.PubMedCrossRef

56.

Desouza CV. Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes? J Diabetes Complications. 2013;27:519–25. doi:https://doi.org/10.1016/j.jdiacomp.2013.04.007.PubMedCrossRef

57.

Saeidnia S, Abdollahi M. Toxicological and pharmacological concerns on oxidative stress and related diseases. Toxicol Appl Pharmacol. 2013;273:442–55.PubMedCrossRef

58.

Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO. Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm. 2008;14:S2–S19.PubMed

59.

Chan SMH, Ye JM. Strategies for the discovery and development of anti-diabetic drugs from the natural products of traditional medicines. J Pharm Pharm Sci. 2013;16:207–16.PubMedCrossRef

60.

Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arc Intern Med. 2005;165:281–6.CrossRef

61.

Akelere O. WHO guidelines for the assessment of herbal medicines. Fitoterapia. 1992;63:99–104.

62.

Astin JA. Why patients use alternative medicine. JAMA. 1998;279:1548–53.PubMedCrossRef

63.

Hasani-Ranjbar S, Larijani B. Medicinal plants as potential new target drugs in endocrine disorders-review article. Iran J Public Health. 2014;43:24–34.

64.

Dabaghian FH, Kamalinejad M, Shojaei A, Fard MA. Presenting anti-diabetic plants in Iranian traditional medicine. J Diabetes Endocrinology. 2012;3:61–7.CrossRef

65.

Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of Iranian medicinal plants useful in diabetes mellitus. Arc Med Sci. 2008;4:285–92.

66.

Kim JD, Kang SM, Park MY, Jung TY, Choi HY, Ku SK. Ameliorative anti-diabetic activity of dangnyosoko, a Chinese herbal medicine, in diabetic rats. Biosci Biotechnol Biochem. 2007;71:1527–34.PubMedCrossRef

67.

Harris CS, Beaulieu LP, Fraser MH, Mcintyre KL, Owen PL, Martineau LC, et al. Inhibition of advanced glycation end product formation by medicinal plant extracts correlates with phenolic metabolites and antioxidant activity. Planta Med. 2011;77:196–204.PubMedCrossRef

68.

Hosseini A, Abdollahi M. Antioxidants as an appropriateapproach to improve the outcome of pancreatic islet isolation:evidences from animal studies. Asian J Anim Ver Adv. 2012;7:540–1.CrossRef

69.

Hosseini A, Abdollahi M. It is time to formulate an antioxidant mixture for management of diabetes and its complications:notice for pharmaceutical industries. Int J Pharmacol. 2012;8:60–1.CrossRef

70.

Miles SL, McFarland M, Niles RM. Molecular and physiological actions of quercetin: the need for clinical trials to assess its benefits in human disease. Nutr Rev. 2014;72:720–34. doi:https://doi.org/10.1111/nure.12152.PubMedCrossRef

71.

Suksmboon N, Poolsup N, Boonkaew S, Suthisisang CC. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol. 2011;137:1328–33. doi:https://doi.org/10.1016/j.jep.2011.07.059.CrossRef

72.

Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm Allergy Drug Targets. 2009;8:2–10.PubMedCrossRef

73.

Prochazkova D, Bousova I, Wilhelmova N. Antioxidant and prooxidant properties of flavonoids. Fitoterapia. 2011;82:513–23. doi:https://doi.org/10.1016/j.fitote.2011.01.018.PubMedCrossRef

74.

Hausenblas HA, Schoulda JA, Smoliga JM: Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus-systematic review and meta-analysis. Mol Nutr Food Res. 2015:59:147-59. doi:https://doi.org/10.1002/mnfr.201400173.

75.

Mitjavila MT, Moreno JJ. The effects of Polyphenols on oxidative stress and the arachidonic acid cascade. Implications for the prevention/treatment of high prevalence diseases. Biochem Pharmacol. 2012;84:1113–22. doi:https://doi.org/10.1016/j.bcp.2012.07.017.PubMedCrossRef

76.

Tabatabaei-Malazy O, Larijani B, Abdollahi M. A systematic review of in vitro studies conducted on effect of herbal products on secretion of insulin from langerhans islets. J Pharm Pharm Sci. 2012;15:447–66.PubMedCrossRef

77.

Kim EK, Kwon KB, Song MY, Seo SW, Park SJ, Ka SO, et al. Genistein protects pancreatic beta cells against cytokine-mediated toxicity. Mol Cell Endocrinol. 2007;278:18–28.PubMedCrossRef

78.

Behloul N, Wu G. Genistein: a promising therapeutic agent for obesity and diabetes treatment. Eur J Pharmacol. 2013;698:31–8.PubMedCrossRef

79.

Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008;75:787–809.PubMedCrossRef

80.

Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631–52. doi:https://doi.org/10.1007/s00018-008-7452-4.PubMedPubMedCentralCrossRef

81.

Tabatabaei-Malazy O, Larijani B, Abdollahi M. A novel management of diabetes by means of strong antioxidants’ combination. J Med Hypotheses Ideas. 2013;7:25–30.CrossRef

82.

Zhang DW, Fu M, Gao SH, Liu JL: Curcumin and diabetes: a systematic review. Evid Based Complement Alternat Med. 2013;2013:636053. doi:https://doi.org/10.1155/2013/636053.

83.

Chartoumpekis DV, Kensler TW. New player on an old field; the Keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome. Curr Diabetes Rev. 2013;9:137–45.PubMedPubMedCentral

84.

Rahimi R, Ghiasi S, Azimi H, Fakhari S, Abdollahi M. A review of the herbal phosphodiesterase inhibitors: future perspective of new drugs. Cytokine. 2010;49:123–9.PubMedCrossRef

85.

Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr. 2004;134:S3479–85.CrossRef

86.

Prabhakar PK, Kumar A, Doble M. Combination therapy: a new strategy to manage diabetes and its complications. Phytomedicine. 2014;21:123–30. doi:https://doi.org/10.1016/j.phymed.2013.08.020.PubMedCrossRef

87.

Ghorbani A, Ghorbani A. Clinical and experimental studies on polyherbal formulations for diabetes: current status and future prospective. J Integr Med. 2014;12:336–45. doi:https://doi.org/10.1016/S2095-4964(14)60031-5.PubMedCrossRef

88.

Mohammadirad A, Khorram-Khrshid HR, Gharibdoost F, Abdollahi M. Setarud (IMODTM) as a multiherbal drug with promising benefits in animal and human studies: a comprehensive review of biochemical and cellular evidences. Asian J Anim Vet Adv. 2011;6:1185–92.CrossRef

89.

Mohseni-Salehi-Monfared SS, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M. Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes. Arch Med Sci. 2010;6:663–9.PubMedPubMedCentralCrossRef

90.

Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–81. doi:https://doi.org/10.1016/S0140-6736(14)60460-8.PubMedPubMedCentralCrossRef

91.

Rippe JM, Angelopoulos TJ: Preventing and managing obesity: the scope of the problem. In: Rippe JM and Angelopoulos TJ (eds), Obesity: prevention and treatmen, 2012, Boca Raton, CRC Press. 3-19.

92.

Skolnik NS, Ryan DH. Pathophysiology, epidemiology, and assessment of obesity in adults. Suppl J Fam Pract. 2014;63:S3–S10.

93.

Angelopoulos TJ: Pathophysiology of obesity. In: Rippe JM and Angelopoulos TJ (ed) Obesity: prevention and treatment. Boca Raton, CRC Press, 2012, 21-32.

94.

Ouchi N, Ohashi K, Shibata R, Murohara T. Adipocytokines and obesity-linked disorders. Nagoya J Med Sci. 2012;74:19–30.PubMedPubMedCentral

95.

Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes, a systematic review and meta-analysis. JAMA. 2009;302:179–88.PubMedCrossRef

96.

Matsuda M, Shimomura I. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014;15:1–10. doi:https://doi.org/10.1007/s11154-013-9271-7.PubMedCrossRef

97.

Milagro FI, Mansego ML, DeMiguel C, Martinez JA. Dietary factors, epigenetic modifications and obesity outcomes: progresses and perspectives. Mol Aspects Med. 2013;34:782–812.PubMedCrossRef

98.

Vomhof-DeKrey EE, Picklo Sr MJ. The Nrf2-antioxidant response element pathway: a target for regulatingenergy metabolism. J Nutr Biochem. 2012;23:1201–6. doi:https://doi.org/10.1016/j.jnutbio.2012.03.005.PubMedCrossRef

99.

Ge Q, Brichard S, Yi X, Li QF. microRNAs as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome. J Immunol Res. 2014;2014:987285. doi:https://doi.org/10.1155/2014/987285.

100.

Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: update meta-analysis. BMJ. 2007;335:1194–9.PubMedPubMedCentralCrossRef

101.

Kim GW, Lin JE, Blomain ES, Waldman SA. Anti-obesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95:53–66. doi:https://doi.org/10.1038/clpt.2013.204.PubMedCrossRef

102.

Bouza C, Lopez-Cuadrado T, Gutierrez-Torres FL, Amate J. Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis. Obes Facts. 2012;5:753–65.PubMedCrossRef

103.

Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann N Y Acad Sci. 2014;1311:1–13.PubMedCrossRef

104.

Bray GA. Medical treatment of obesity: the past, the present and the future. Best Pract Res Clin Gastroenterol. 2014;28:665–84. doi:https://doi.org/10.1016/j.bpg.2014.07.015.PubMedCrossRef

105.

Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5:1218–40. doi:https://doi.org/10.3390/nu5041218.PubMedPubMedCentralCrossRef

106.

Aronne LJ. Evolving directions in obesity management. J Fam Pract. 2014;63:S27–33.PubMed

107.

Abdollahi M, Afshar-Imani B. A review on obesity and weight loss measures. Middle East Pharmacy. 2003;11:6–10.

108.

Yun JW. Possible anti-obesity therapeutics from nature-a review. Phytochemistry. 2010;71:1625–41.PubMedCrossRef

109.

Hasani-Ranjbar S, Nayebi N, Larijani B, Abdollahi M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol. 2009;15:3073–85.PubMedPubMedCentralCrossRef

110.

Hasani-Ranjbar S, Jouyandeh Z, Abdollahi M. A systematic review of anti-obesity medicinal plants- an update. J Diabetes Metab Disord. 2013;12:28. doi:https://doi.org/10.1186/2251-6581-12-28.PubMedPubMedCentralCrossRef

111.

Gonzalez-Castejon M, Rodriguez-Casado A. Dietary Phytochemicals and their potential effects on obesity: a review. Pharmacol Res. 2011;64:438–55. doi:https://doi.org/10.1016/j.phrs.2011.07.004.PubMedCrossRef

112.

Hill AM, Buckley JD, Murphy KJ, Howe PR. Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am J Clin Nutr. 2007;85:1267–74.PubMedCrossRef

113.

Lorente-Cebrian S, Costa AGV, Navas-Carretero S, Zabata M, Martinez JA, Moreno-Aliaga MJ. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular disease: a review of the evidence. J Physiol Biochem. 2013;69:633–51. doi:https://doi.org/10.1007/s13105-013-0265-4.PubMedCrossRef

114.

Rayalam S, Della-Fera MA, Baile CA. Synergism between resveratrol and other phytochemicals: implications for obesity and osteoporosis. Mol Nutr Food Res. 2011;55:1177–85.PubMedCrossRef

115.

Park JH, Lee MJ, Song MY, Bose S, Shin BC, Kim HJ. Efficacy and safety of mixed orental herbal medicines for treating human obesity: a systematic review of randomized clinical trials. J Med Food. 2012;15:589–97. doi:https://doi.org/10.1089/jmf.2011.1982.PubMedCrossRef

116.

Rosenson RS, Freeman MW, Saperia GM: HDL-cholesterol: Clinical aspects of abnormal values. Available in www.UpToDate.com. Accessed 2015.

117.

Alwan A. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. Report World Health Organization. Published 2009. Available in http://www.who.int/nmh/ publications/9789241597418/en.

118.

Wang SY, HHsieh MC, Tu ST, Chuang CS. New frontiers in the treatment of diabetic dyslipidemia. Rev Diabet Stud. 2013;10:204–12. doi:https://doi.org/10.1900/RDS.2013.10.204.PubMedPubMedCentralCrossRef

119.

Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. 2010;459:923–39.PubMedCrossRef

120.

Salari Sharif P, Abdollahi M. A systematic review on the relation between use of statins and osteoporosis. Int J Pharmacol. 2011;7:180–8.CrossRef

121.

Pajouhi M, Mohajeri-Tehrani MR, Fakhrzadeh H, Tabatabaei-Malazy O, Amini P. Lipid disorders. In: Arzaghi M, Tabatabaei-Malazy O, editors. Lipid disorders in Persian language. Iran: Vista; 2011. p. 1–217.

122.

Aranda JF, Madrigal-Matute J, Rotllan N, Fernández-Hernando C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radic Biol Med. 2013;64:31–9. doi:https://doi.org/10.1016/j.freeradbiomed.2013.07.014.PubMedPubMedCentralCrossRef

123.

Pignone M, Freeman MW, Rind DM: Treatment of lipids (including hypercholesterolemia) in primary prevention. Available in www.UpToDate.com. Accessed 2015.

124.

Nikolic D, Nikfar S, Salari P, Rizzo M, Ray KK, Pencina MJ, et al. Effects f statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2013;29:435–51. doi:https://doi.org/10.1185/03007995.2013.779237.PubMedCrossRef

125.

Tinkel J, Hassanain H, Khouri SJ. Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms. Cardiol Rev. 2012;20:77–83.PubMedCrossRef

126.

Hamilton SJ, Watts GF. Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. Rev Diabet Stud. 2013;10:191–203. doi:https://doi.org/10.1900/RDS.2013.10.191.PubMedPubMedCentralCrossRef

127.

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2014;37:S14–80. doi:https://doi.org/10.2337/dc14-S014.CrossRef

128.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. tatins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735–42. doi:https://doi.org/10.1016/S0140-6736(09)61965-6.PubMedCrossRef

129.

Wong CP, Kaneda T, Morita H. Plant natural products as an anti-lipid droplets accumulation agent. J Nat Med. 2014;68:253–66. doi:https://doi.org/10.1007/s11418-014-0822-3.PubMedPubMedCentralCrossRef

130.

Hasani-Ranjbar S, Nayebi N, Larijani B, Abdollahi M. A systematic review of the efficacy and safety of Teucrium species: from anti-oxidant to anti-diabetic effects. Int J Pharmacol. 2010;6:315–25.CrossRef

131.

Hasani-Ranjbar S, Nayebi N, Moradi L, Mehri A, Larijani B, Abdollahi M. The efficacy and safety of herbal medicines used in the treatment of hyperlipidemia; a systematic review. Cur Pharm Des. 2010;16:2935–47.CrossRef

132.

Momtaz S, Abdollahi M. An update on pharmacology of Satureja species; from antioxidant, antimicrobial, antidiabetes and anti-hyperlipidemic to reproductive stimulation. Int J Pharmacol. 2010;6:454–61.CrossRef

133.

Reinhart KM, Talati R, White CM, Coleman CI. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev. 2009;22:39–48. doi:https://doi.org/10.1017/S0954422409350003.PubMedCrossRef

134.

Mozaffari S, Hasani-Ranjbar S, Abdollahi M. The mechanisms of positive effects of melatonin in dyslipidemia: a systematic review of animal and human studies. Int J Pharmacol. 2012;8:496–509. doi:https://doi.org/10.3923/ijp.2012.496.509.CrossRef

135.

Mozaffari S, Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr Pharm Des. 2011;17:4372–8.PubMedCrossRef

136.

Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106:286–8.PubMedCrossRef

137.

O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obesity Rev. 2011;16:1–12. doi:https://doi.org/10.1111/obr.12229.CrossRef

138.

Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. Am J Coll Cardiol. 2012;59:635–43. doi:https://doi.org/10.1016/j.jacc.2011.08.080.CrossRef

139.

Meigs JB, Nathan DM, Wolfsdorf JI, Mulder JE: The metabolic syndrome (insulin resistance syndrome or syndrome X). Available in www.UpToDate.com. Accessed 2015.

140.

Skalicky J, Muzakova V, Kandar R, Meloun M, Rousar T, Palicka V. Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med. 2008;46:499–505.PubMedCrossRef

141.

Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis. 2010;20:140–6. doi:https://doi.org/10.1016/j.numecd.2009.08.006.PubMedCrossRef

142.

Lim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord. 2014;15:329–41. doi:https://doi.org/10.1007/s11154-014-9298-4.PubMedCrossRef

143.

Galleano M, Calabro V, Prince PD, Litterio MC, Piotrkowski B, Vazquez-Prieto MA, et al. Flavonoids and metabolic syndrome. Ann N Y Acad Sci. 2012;1259:87–94.PubMedCrossRef

144.

Cederroth CR, Nef S. Soy, phytoestrogens and metabolism: a review. Mol Cell Endocrinol. 2009;304:30–42.PubMedCrossRef

145.

Power M, Pratley R. Alternative and complementary treatments for metabolic syndrome. Curr Diab Rep. 2011;11:173–8. doi:https://doi.org/10.1007/s11892-011-0184-0.PubMedCrossRef

146.

Graf BL, Raskin I, Cafalu WT, Ribnicky DM. Plant-derived therapeutics for the treatment of metabolic syndrome. Curr Opin Investig Drugs. 2010;11:1107–15.PubMedPubMedCentral

147.

World Health Organization: WHO scientific group on the assessment of osteoporosis at the primary health care level. Summary Meeting Report; Brussels, Belgium. 5–7 May 2004; World Health Organization; 2007.

148.

International Ostoporosis Foundation. Osteoporosis. Available in www.iofbonehealth.org. Last accessed 20 Jan 2015.

149.

Crockett JC, Rogers MJ, Coxon FP, Hocking LJ, Helfrich MH. Bone remodeling at a glance. J Cell Sci. 2011;124(Pt 7):991–8. doi:https://doi.org/10.1242/jcs.063032.PubMedCrossRef

150.

Rao LG, Rao AV: Oxidative stress and antioxidants in the risk of osteoporosis-role of the antioxidants lycopene and polyphenols. Topics in Osteoporosis, Dr. Margarita Valdés-Flores (Ed.), ISBN: 978-953-51-1066-8, InTech, 117-162.DOI: https://doi.org/10.5772/54703. Available from: http://www.intechopen.com/books/topics-in-osteoporosis/oxidative-stress-and-antioxidants-in-the-risk-of-osteoporosis-role-of-the-antioxidants-lycopene-and-2013

151.

DePaula FJA, Rosen CJ. Obesity, diabetes mellitus and last but not least, osteoporosis. Arq Bras Endocrinol Metab. 2010;54:150–7.CrossRef

152.

Aynardi M, Ilyas AF. Pharmacologic management of osteoporosis. J Hand Surg [Am]. 2013;38:588–92. doi:https://doi.org/10.1016/j.jhsa.2012.11.023.CrossRef

153.

Reid IR. Osteoporosis treatment: focus on safety. Eur J Intern Med. 2013;24:691–7. doi:https://doi.org/10.1016/j.ejim.2013.03.012.PubMedCrossRef

154.

Jain SK, Micinski D. Vitamin D upregulates glutamate cystein ligase and glutathione reductase, and GSH formation, and decrease ROS and MCP-1 and IL-8 secretion in high-glucose exposed U937 monocytes. Biochem Biophys Res Commun. 2013;437:7–11. doi:https://doi.org/10.1016/j.bbrc.2013.06.004.PubMedPubMedCentralCrossRef

155.

Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92:2017–29.PubMedCrossRef

156.

Schuiling KD, Robinia K, Nye R. Osteoporosis update. J Midwifery Womens Health. 2011;56:615–27. doi:https://doi.org/10.1111/j.1542-2011.2011.00135.x.PubMedCrossRef

157.

Das S, Crockett JC. Osteoporosis- a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013;7:435–48.PubMedPubMedCentral

158.

Varenna M, Bertoldo F, Di Monaco M, Giusti A, Martini G, Rossini M, et al. Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo. 2013;65:143–66.PubMedCrossRef

159.

Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91:2011–6.PubMedCrossRef

160.

Laurent M, Gielen E, Claessens F, Boonen S, Vanderschueren D. Osteoporosis in older men: recent advances in pathophysiology and treatment. Best Pract Res Clin Endocrinol Metab. 2013;27:527–39. doi:https://doi.org/10.1016/j.beem.2013.04.010.PubMedCrossRef

161.

Banu J. Cause, consequences, and treatment of osteoporosis in men. Drug Des Devel Ther. 2013;7:849–60. doi:https://doi.org/10.2147/DDDT.S46101.PubMedPubMedCentralCrossRef

162.

Salari Sharif P, Asalforoush M, Ameri F, Larijani B, Abdollahi M. The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age (Dordr). 2010;32:179–86.PubMedCrossRef

163.

Depypere HT, Comhaire FH. Herbal preparations for the menopause: beyond isoflavones and black cohosh. Maturitas. 2014;77:191–4. doi:https://doi.org/10.1016/j.maturitas.2013.11.001.PubMedCrossRef

164.

Poluzzi E, Piccinni C, Raschi E, Rampa A, Recannatini M, DePonti F. Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective. Cur Med Chem. 2014;21:417–36.CrossRef

165.

Taku K, Melby MK, Nishi N, Omori T, Kurzer MS. Soy isoflavones for osteoporosis: an evidence-based approach. Maturitas. 2011;70:333–8.PubMedCrossRef

166.

Wei P, Liu M, Chen Y, Chen DC. Systematic review of soy isoflavones supplements on osteoporosis in women. Asian Pac J Trop Med. 2012;3:243–8. doi:https://doi.org/10.1016/S1995-7645(12)60033-9.CrossRef

167.

Salari P, Rezaei A, Larijani B, Abdollahi M. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med Sci Monit. 2008;14:RA37–44.PubMed

Title: Targeting metabolic disorders by natural products
Authors: Ozra Tabatabaei-Malazy
Bagher Larijani
Mohammad Abdollahi
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2015
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1186/s40200-015-0184-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

The association of vitamin D deficiency with psychiatric distress and violence behaviors in Iranian adolescents: the CASPIAN-III study

Effect of metabolic control on oxidative stress, subclinical atherosclerosis and peripheral artery disease in diabetic patients

Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting

RETRACTED ARTICLE: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment

The association between periodontal disease and metabolic syndrome among outpatients with diabetes in Jordan

Markers of adiposity among children and adolescents: implications of the isotemporal substitution paradigm with sedentary behavior and physical activity patterns

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials